Welcome to our dedicated page for Actinium Pharmac SEC filings (Ticker: ATNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Actinium Pharmaceuticals filings document governance and public-company reporting for a biopharmaceutical issuer whose common stock is registered on the NYSE American under ATNM. Recent Current Reports and proxy materials cover annual meeting matters, Class III director elections, advisory votes on executive compensation, principal financial officer changes, and registered common stock details.
The company's proxy disclosures connect shareholder voting matters with board structure, compensation oversight, and annual-report materials. Form 8-K filings record material events and amendments to prior event reports, including officer-transition disclosures and the final reporting of annual meeting voting outcomes.
Actinium Pharmaceuticals (ATNM) reported no revenue for the quarter and six months and recorded a net loss of $6.9 million for the three months and $22.8 million year-to-date, or $0.73 per share for six months on 31.2 million shares outstanding. Cash and cash equivalents totaled $59.9 million (plus $0.3 million restricted cash) versus $72.9 million at year-end, and stockholders’ equity declined to $19.0 million from $32.8 million.
The company recorded $8.8 million of stock-based compensation in the six-month period related to the cancellation of options, and operating expenses were $24.1 million for six months, driven by R&D and G&A. License consideration of $35.0 million received under its Immedica agreement remains recorded as long-term deferred revenue until EU regulatory milestones are satisfied. Material legal actions include a securities class action and consolidated derivative complaints; lead plaintiffs were recently appointed.
The Vanguard Group has filed Amendment No. 1 to Schedule 13G for Actinium Pharmaceuticals (ATNM), triggered by the 30 June 2025 reportable event. The filing discloses 1,371,840 ATNM common shares beneficially owned, equal to 4.39 % of the outstanding class, placing Vanguard below the 5 % threshold noted in Item 5.
According to Item 4, Vanguard holds no voting power—sole or shared—but retains dispositive authority over nearly all of the shares (sole: 1,362,947; shared: 8,893). Vanguard is filing in its capacity as an investment adviser (Rule 13d-1(b)(1)(ii)(E)); the ownership is on behalf of its advisory clients, none of which individually own more than 5 %. Certification in Item 10 confirms the stake is held in the ordinary course of business and not for the purpose of influencing control of ATNM.